Stocks and Investing Stocks and Investing
Fri, January 24, 2025
[ Last Fri ] - WOPRAI
Wamsi Mohan Maintained (AAPL) at Buy with Decreased Target to $253 on, Jan 24th, 2025
[ Last Fri ] - MSN
Brinker International's SWOT analysis: stock's growth momentum faces valuation hurdles
[ Last Fri ] - MSN
Victoria's Secret & Co.'s SWOT analysis: stock outlook amid leadership change
[ Last Fri ] - MSN
Vanguard's U.S. stock-market call is even more shocking than you realize
[ Last Fri ] - MSN
Investing $10,000 in These 2 Stocks Could Make You $100,000 Richer
[ Last Fri ] - MSN
GE's SWOT analysis: aerospace giant's stock soars on aftermarket growth
[ Last Fri ] - MSN
1 Delectable Dividend Stock Down 11% to Buy Now and Hold
[ Last Fri ] - MSN
Walmart CEO Doug McMillon sells $2.7 million in company stock
[ Last Fri ] - Investing
FTSE 100 retreats from record to fall; Storm Eowyn batters Ireland and Scotland
[ Last Fri ] - MSN
Cantor initiates coverage on Space sector stocks
[ Last Fri ] - MSN
Invest $20,000 in 2 TSX Stocks for $3,442.44 in Passive Income
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of TURN at $3 .. 05, after crossing above the $3.801 Trigger Price
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of LMFA at $2 .. 235, after crossing above the $2.22 Trigger Price
[ Last Fri ] - MSN
Morgan Stanley sees defensive plays as key in challenging energy market
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of CLI at $15 .. 3, after crossing above the $15.729 Trigger Price
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of WTMF at $3 .. 9, after crossing above the $35.635 Trigger Price
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of PRFX at $5 .. 91, after crossing above the $4.704 Trigger Price
[ Last Fri ] - Investopedia
How to Invest in Uncertain Times
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of APVO at $4 .. 92, after crossing above the $4.739 Trigger Price
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of VICI at $2 .. 5, after crossing above the $29.642 Trigger Price
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of NAVI at $1 .. 5, after crossing above the $14.685 Trigger Price
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of CLSK at $1 .. 5, after crossing above the $11.791 Trigger Price
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of BOW at $31 .. 1, after crossing above the $31.724 Trigger Price
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of ALGT at $1 .. , after crossing above the $103.224 Trigger Price
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of ACKDF at $ .. 35, after crossing above the $4.982 Trigger Price
[ Last Fri ] - FXStreet
Trump trade back in vogue - Societe Generale
[ Last Fri ] - Morningstar
Why Inflation Still Poses a Risk to Stocks and Bonds in 2025
[ Last Fri ] - WOPRAI
Short squeeze is starting in shares of AIN at $81 .. 8, after crossing above the $80.821 Trigger Price
[ Last Fri ] - MSN
Intuitive Surgical, American Express Stir Friday's Market Cap Stock Movers
[ Last Fri ] - Kiplinger
Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy


Published on 2025-01-24 12:01:12 - Kiplinger
  Print publication without navigation

  • Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

The article from Kiplinger discusses the investment potential of Novo Nordisk (NVO), a Danish pharmaceutical company, focusing on its recent developments in weight loss drugs. Novo Nordisk has shown promising results with its drug semaglutide, marketed as Wegovy for weight loss, which has led to significant stock price increases. The company's shares have risen by 45% in the past year, outperforming the S&P 500. Analyst evaluations, including from Barclays, have given Novo Nordisk an "overweight" rating, citing the company's strong market position in diabetes and obesity treatments. The article highlights the potential for further growth due to the expanding market for obesity treatments, with Wegovy's sales expected to grow as it gains more market share. However, it also notes concerns about supply constraints and competition from other pharmaceutical companies like Eli Lilly. Overall, the consensus seems to lean towards a buy rating for Novo Nordisk stock, driven by its innovative treatments and robust pipeline in metabolic disorders.

Read the Full Kiplinger Article at:
[ https://www.kiplinger.com/investing/stocks/novo-nordisk-nvo-stock-weight-loss-drug-data-buy-rating ]
Contributing Sources